{"id":77118,"date":"2026-04-17T05:22:07","date_gmt":"2026-04-17T05:22:07","guid":{"rendered":"https:\/\/www.europesays.com\/be-fr\/77118\/"},"modified":"2026-04-17T05:22:07","modified_gmt":"2026-04-17T05:22:07","slug":"gustave-roussy-met-au-point-un-logiciel-dia-pour-la-detection-du-cancer-a-limagerie","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/be-fr\/77118\/","title":{"rendered":"Gustave Roussy met au point un logiciel d&rsquo;IA pour la d\u00e9tection du cancer \u00e0 l&rsquo;imagerie"},"content":{"rendered":"<p>La promesse d&rsquo;un suivi plus rapide et pr\u00e9cis des patients atteints de cancer. Le centre de lutte contre le cancer Gustave-Roussy (Villejuif, 94), le CHU d\u2019Angers, le laboratoire Guerbet et l&rsquo;entreprise Intrasense ont d\u00e9velopp\u00e9 ensemble\u00a0un outil d\u2019intelligence artificielle capable d\u2019analyser de mani\u00e8re exhaustive les l\u00e9sions canc\u00e9reuses sur des examens de scanner thoraco-abdomino-pelvien. Baptis\u00e9 DuOnco Unity\u00ae, il est pr\u00e9sent\u00e9 dans <a href=\"https:\/\/www.gustaveroussy.fr\/fr\/un-nouvel-outil-dia-au-service-dune-detection-optimale-du-cancer-par-imagerie\" rel=\"nofollow noopener\" target=\"_blank\">un communiqu\u00e9 diffus\u00e9 le 7\u00a0avril par Gustave-Roussy<\/a>.<\/p>\n<p>Une r\u00e9ponse aux limites des m\u00e9thodes actuelles<\/p>\n<p>Aujourd\u2019hui, l\u2019\u00e9valuation de l\u2019efficacit\u00e9 des traitements anticanc\u00e9reux repose principalement sur les crit\u00e8res RECIST, un standard bas\u00e9 sur la mesure d\u2019un nombre limit\u00e9 de l\u00e9sions dites \u00ab\u00a0cibles\u00a0\u00bb, rappelle le communiqu\u00e9. Si cette m\u00e9thode a fait ses preuves, elle pr\u00e9sente toutefois des limites importantes, notamment chez les patients avec un grand nombre de m\u00e9tastases r\u00e9parties sur plusieurs organes.<br \/>Dans un contexte o\u00f9 la m\u00e9decine de pr\u00e9cision exige une compr\u00e9hen<\/p>\n","protected":false},"excerpt":{"rendered":"La promesse d&rsquo;un suivi plus rapide et pr\u00e9cis des patients atteints de cancer. Le centre de lutte contre&hellip;\n","protected":false},"author":2,"featured_media":77119,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[82],"tags":[12,13,18,17,86,451,176,7991,87],"class_list":{"0":"post-77118","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-be","9":"tag-be-fr","10":"tag-belgique","11":"tag-belgium","12":"tag-health","13":"tag-intelligence-artificielle","14":"tag-logiciel","15":"tag-oncologie","16":"tag-sante"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@be_fr\/116418376101217353","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/posts\/77118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/comments?post=77118"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/posts\/77118\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/media\/77119"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/media?parent=77118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/categories?post=77118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/be-fr\/wp-json\/wp\/v2\/tags?post=77118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}